Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
about
Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) andRandomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.Human papillomavirus and survival of patients with oropharyngeal cancer.How individual participant data meta-analyses have influenced trial design, conduct, and analysisTime-dependent endpoints as predictors of overall survival in multiple myelomaSurrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.Multivariate meta-analysis using individual participant data.Impact of comprehensive geriatric assessment on survival, function, and nutritional status in elderly patients with head and neck cancer: protocol for a multicentre randomised controlled trial (EGeSOR)Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancerSignificance of lymph node metastasis in cancer dissemination of head and neck cancerEndpoints in advanced breast cancer: methodological aspects & clinical implications.Lower platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma: a retrospective analysisSurrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.Emerging insights into head and neck cancer metastasis.Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.Circulating and disseminated tumour cells in head and neck cancer.Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents.A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses.Hyperthermia and radiotherapy in the management of head and neck cancers: A systematic review and meta-analysis.Prognostic significance of clinical and 18 F-FDG PET/CT parameters for post-distant metastasis survival in head and neck squamous cell carcinoma patients.Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.Personalized dynamic prediction of death according to tumour progression and high-dimensional genetic factors: Meta-analysis with a joint model.EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.A joint frailty-copula model between tumour progression and death for meta-analysis.Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer.Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points.Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.Bcl-xL protein: predictor of complete tumor response in patients with oral cancer treated with curative radiotherapy.Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data.Prognostic factors for supraglottic laryngeal carcinoma: Importance of the unfit patient.
P2860
Q27025943-118B9B8B-29E8-43B0-892B-20CEF8177F57Q27313572-6AF4F185-4FFE-43F7-AB86-5D4926857B8EQ27851567-657A0E34-B3E7-4A38-A0B8-25384D827B48Q28607751-E27022FE-A5F5-4C94-B820-7ACA5D23118EQ30538040-5660CB23-1AA6-4476-B1F3-D96F4CC3BF1BQ30627447-61A18242-486E-409C-B5C9-8022419C2FEDQ30976009-50975362-EF31-4975-8F80-BECDDDF3F2E5Q33844620-6ED6F1C8-1A54-4D5C-A7A1-61231696226DQ34171999-A35DCFB0-CCD9-465B-9DE9-B51C612DA670Q34332841-235944A5-0549-4322-A7A5-581227080577Q35190699-047BA980-9065-4633-934E-332200AA71B0Q35206363-1376A818-72C4-4095-802F-BFD708D7093FQ35555487-666D7246-304F-45E1-9BFB-31FB7B2429ECQ35611036-A46D65FC-2FDB-4810-9695-4DE05C6714D6Q36126155-95CCDD3F-100B-49F6-B81A-09CA9F35008EQ36215439-8F3D226C-1527-4472-B665-ABDA3C84C5DFQ36349459-1E8C6D3F-0CA1-418A-94C2-A98364E6E168Q37631295-89AB8DDD-E795-40F6-8046-4D0DFA51B931Q37676732-E4757C09-A37A-40CF-A0EA-8EF67CAC6996Q38070999-717DAAD0-90CF-42A1-9E3A-FC126CE82488Q38312486-FC3C9AE5-66F5-47E2-82D1-F6580AFA15C7Q38356102-2A2B2CE7-6972-4BCF-91B7-BCFC484C25E3Q38547000-B76FD72D-84E4-499A-8AD8-A6606E331FBEQ38636718-3F9ABA8E-8826-419C-9860-D97FA77A96F2Q38691539-D6BDB673-A1A4-4A71-A39C-2174276D29D3Q38755736-F14677F6-F425-4FA7-A038-5E5EEF584D87Q38803920-E34B9CCD-A69A-44F8-8DC9-986158870AEDQ38880510-7E1D34B9-1C2D-4A1B-BA9E-ED3214028FEAQ39019006-BE1A8316-CC88-4E54-8FE5-C2FFF133DB3FQ39094519-C7A5AB34-872C-4B57-B088-8E83C361412DQ39933767-32E26E64-B49A-434D-9AB5-43DEB4E1BDC4Q40525129-B4CDF160-C94A-4044-880D-9192A8C81E45Q41514384-2E022157-93D7-4C56-942A-D9EA4446DE2DQ41756947-444A7ECB-7EC3-49F0-B317-1F242A6EB62CQ41782195-2C49670D-112C-488B-9FA7-EA8225BCB17EQ41865845-E17DAEF3-FE37-4BA7-A9FA-7BED89DF03A7Q42852367-F0196BCD-D846-4232-9804-9A12F20914A7Q44736357-A870872F-74C0-404E-8A3B-9F59EAA890BCQ47098597-BF1D71AF-5500-4837-8EDA-2D1A4767CD99Q47581242-046A8741-C079-4362-9B5D-250C6732AECD
P2860
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Surrogate endpoints for overal ...... es of individual patient data.
@ast
Surrogate endpoints for overal ...... es of individual patient data.
@en
type
label
Surrogate endpoints for overal ...... es of individual patient data.
@ast
Surrogate endpoints for overal ...... es of individual patient data.
@en
prefLabel
Surrogate endpoints for overal ...... es of individual patient data.
@ast
Surrogate endpoints for overal ...... es of individual patient data.
@en
P2093
P50
P1433
P1476
Surrogate endpoints for overal ...... es of individual patient data.
@en
P2093
Aurélie Le Maître
Emilie Maillard
Jan B Vermorken
Jan Bogaerts
Jean Bourhis
Kian K Ang
MARCH and MACH-NC Collaborative Groups
Thomas F Pajak
Wilfried Budach
P304
P356
10.1016/S1470-2045(09)70023-3
P577
2009-02-24T00:00:00Z